Y-Mabs Therapeutics (YMAB) EBITDA (2018 - 2025)
Y-Mabs Therapeutics (YMAB) EBITDA from Sep 30, 2018 to Jun 30, 2025. The TTM Y-Mabs Therapeutics (YMAB) EBITDA is -$26M. You can adjust inflation or export chart.
Annual EBITDA
Quarterly EBITDA
Y-Mabs Therapeutics (YMAB) EBITDA CAGR table
| Period | CAGR |
|---|---|
| 1 Year TTM | -2.18% |
| 3 Years TTM | -41.40% |
| 5 Years TTM | -25.48% |
| All Time TTM | -16.24% |
Annual EBITDA change of Y-Mabs Therapeutics (YMAB)
| Year | EBITDA | Change |
|---|---|---|
| 2025 | -$12M | -60.81% |
| 2024 | -$31M | +22.98% |
| 2023 | -$25M | -73.46% |
| 2022 | -$94M | -18.04% |
| 2021 | -$115M | -4.09% |
| 2020 | -$120M | +44.30% |
| 2019 | -$83M | +91.76% |
| 2018 | -$43M | N/A |